4
Changes in Ownership
Roivant Sciences Ltd. Filed Acc 0001140361-26-030107
President & Immunovant CEO sold 200,000 shares at $34.95 ($6,990,000)
- President & Immunovant CEO acquired 200,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Venker Eric President & Immunovant CEO | 2026-07-27 | Option exercise 10b5-1 | +200,000 | $3.85 | $770,000 | 1,813,063 | D |
| Venker Eric President & Immunovant CEO | 2026-07-27 | Sale 10b5-1 | −200,000 | $34.95 | $6,990,000 | 1,613,063 | D |
| Derivatives | |||||||
| Venker Eric President & Immunovant CEO | 2026-07-27 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −200,000 | 4,044,834 | D | ||
| Open-market sales · 200,000 sh · avg $34.95 · $6,990,000 | |||||||
Loading xslF345X06/form4.xml…